18-012 - Clinical Trial to Learn if the Usual Chemotherapy, given before Surgery (Neoadjuvant Therapy) for Breast Cancer plus an Experimental Drug, is Better than the Usual Chemotherapy plus a PlaceboStatus: open
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo
Treatment for Breast Cancer
If you have questions about this trial or are interested in participating, please contact this Clinical Trial’s Coordinator by email at email@example.com.
The main purpose of this study is to learn if the usual chemotherapy given before surgery (neoadjuvant therapy) for breast cancer plus the experimental drug, atezolizumab, is better than the usual chemotherapy plus a placebo. IRB Number 18-012
SponsorsThis trial is sponsored by NSABP.
Providers Associated With This Trial
- Donna Lynn Dyess, M.D., F.A.C.S.Breast/Endocrine SurgeonProfessor of Surgery